Drug Database
DO

donepezil + memantine ER (ADS8703 / Arimenda / ADS8704)

✓ Approved

Forest Laboratories Inc. · ACHE · 小分子

什么是 donepezil + memantine ER?

donepezil + memantine ER 是一种小分子,由Forest Laboratories Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名ADS8703, Arimenda, ADS8704
公司Forest Laboratories Inc.
药物类别小分子
分子靶点ACHE, GRIN1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

donepezil + memantine ER 作用于 2 个分子靶点:

ACHEacetylcholinesterase (Cartwright blood group) (N-ACHE, ACEE)
GRIN1glutamate ionotropic receptor NMDA type subunit 1 (NMD-R1, NMDA1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

donepezil + memantine ER 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersDementia Alzheimer's type✓ Approved

相关研究文献

PubMedInternational psychogeriatrics2026-11-19

Corrigendum to 'Memantine in Korean Alzheimer's disease: A prospective real-world REMIND study' [Int. Psychogeriat. (2026) 100298].

Na Seunghee S, Kim Hyun Sook HS, Kim Geon Ha GH, Kwon Oh Dae OD et al.

PMID 43053509
阅读全文 →
PubMedBMC neurology2026-11-19

Therapeutic regimen for AD-derived MCI: the effect of sodium oligomannate (GV-971) combined with donepezil on patients' cognitive function and hippocampal atrophy rate.

Jiao Fucheng F, Li Yuhua Y, Zhang Lina L, Fang Caixia C et al.

To investigate the clinical efficacy of sodium oligomannate (GV-971) combined with donepezil in the treatment of patients with mild cognitive impairment (MCI) in Alzheimer's disease (AD). This non-randomized, open-label, retrospective analytic study included 100 patients with AD-derived MCI who were treated in our hospital between May 2023 and May 2024, and were divided into two groups according to the different treatment modalities recorded in the electronic medical record system: 44 cases in the control group (donepezil), and 56 cases in the observation group (sodium oligomannate (GV-971) combined with donepezil). Cognitive function, biochemical markers (homocysteine (Hcy), S100 calcium binding protein B (S100β), neuron-specific enolase (NSE)), serum intestinal flora metabolic markers (phenylalanine (Phe), short-chain fatty acids (SCFA), γ-aminobutyric acid (GABA), acetylcholine (Ach)), hippocampal volume, and adverse effects were collected and compared between the two groups, and adverse reactions were recorded. After treatment, the comparison of various scores of cognitive function, Hcy, S100β, NSE, Phe, SCFA, GABA, and Ach between the patients in the observation group and the control group showed statistically significant differences (P<0.05); after treatment, the comparison of left hippocampal volume, right hippocampal volume, and total volume between the observation group and the control group did not show any statistically significant difference (P>0.05). In contrast, the calculated hippocampal atrophy rate-derived from the percentage change relative to baseline volume-was significantly lower in the observation group than in the control group (P < 0.05). Regarding safety, the total incidence of adverse reactions was 10.71% (6/56) in the observation group versus 9.09% (4/44) in the control group, with no statistically significant difference between the two groups (P > 0.05). The combination of sodium oligomannate (GV-971) and donepezil was associated with more favorable changes in cognitive function, neuronal injury biomarkers, serum markers of gut microbiota metabolism, and a slower observed rate of hippocampal atrophy in patients with AD-derived MCI. These associations do not imply causation, and the combination regimen did not significantly increase adverse reactions in this cohort.

PMID 43052811
阅读全文 →
PubMedNature reviews. Molecular cell biology2026-11-19

Regulation and cellular functions of ERphagy.

Rudinskiy Mikhail M, Molinari Maurizio M

ERphagy, the lysosomal turnover of endoplasmic reticulum (ER) subdomains, sustains ER function by adapting ER architecture and content to changing cellular demands. It operates constitutively and is enhanced either as one of the cellular programmes triggered by nutrient restriction or during cellular differentiation, or, more selectively, by ER-centric cues such as recovery from ER stress, defective protein translocation in the ER, or the accumulation of misfolded polypeptides in the ER lumen or membrane. In this Review, we discuss how membrane-associated and soluble ERphagy receptors cooperate with chaperones, adaptors, membrane-remodelling factors and core autophagy proteins to select cargo, delimit ER subdomains, separate them from the continuous ER network and coordinate their lysosomal delivery. We cover recent findings on the mechanisms, activation and regulation of ERphagy and of the related ER-to-lysosome-associated degradation pathways, and on their roles in physiology and disease. Finally, we consider therapeutic strategies that target ERphagy to selectively restore ER homeostasis or eliminate harmful ER content.

PMID 43052560
阅读全文 →
PubMedMolecular medicine (Cambridge, Mass.)2026-11-19

ER stress and structural changes induced by rare WFS1 variant identified in autosomal dominant form of WFS1-related disorder.

Borecka Silvia S, Zahradnikova Alexandra A, Varga Lukas L, Stanik Juraj J et al.

WFS1‑related disorders encompass a broad phenotypic spectrum ranging from classical autosomal-recessive Wolfram syndrome to autosomal-dominant Wolfram‑like disorders. Dominant variants may disrupt endoplasmic reticulum (ER) homeostasis, calcium handling, and ER-mitochondria communication. Here, we report a Slovak male patient with a complex multisystem Wolfram‑like phenotype and identify a rare heterozygous in‑frame deletion in WFS1 (c.2608_2619del, p.870_873del). We aimed to determine its pathogenic potential through structural modelling and functional assays. The genetic aetiology was investigated by Sanger sequencing, WGS and MLPA. Structural consequences of the deletion were analysed using AlphaFold3 modelling of wild‑type and mutant wolframin, followed by hydrogen‑bond quantification in ChimeraX. Functional studies were performed in HeLa cells expressing wild‑type WFS1, the rare p.870_873del variant, and two pathogenic controls (p.E809K, p.P724L). ER morphology was assessed by confocal microscopy. ER stress activation was quantified using ERSE‑luciferase reporter assays, XBP1 splicing analysis, and qPCR of UPR‑related genes. Mitochondrial fusion dynamics were measured using the photoconvertible mito‑KikGR1 system. The patient presented with early‑onset insulin‑dependent diabetes mellitus, bilateral cataracts, sensorineural hearing loss, autism spectrum disorder, paroxysmal events, and additional systemic comorbidities. Genetic analysis identified a de novo in‑frame deletion affecting four amino acid residues. Structural modelling showed that the deleted region contributes to a C‑terminal hydrogen‑bonding network, and its loss resulted in a significant reduction of stabilizing interactions. Although ER morphology remained preserved, cells expressing the p.870_873del variant displayed markedly reduced mitochondrial fusion, comparable to both pathogenic controls, indicating impaired ER-mitochondria crosstalk. Functional assays further demonstrated pronounced ER stress, evidenced by significantly increased ERSE‑luciferase activity, increased XBP1 splicing, upregulation of DDIT3 (CHOP), and mild induction of HSPA5 (BiP), consistent with activation of the unfolded protein response. We identified a rare likely pathogenic p.870_873del WFS1 variant associated with an autosomal-dominant WFS1‑related disorder and a multisystem Wolfram‑like phenotype. Combined structural and functional evidence indicates that this variant disrupts protein stability, activates ER stress, and impairs ER-mitochondria communication, supporting its potential pathogenic role.

PMID 43052710
阅读全文 →
PubMedNPJ breast cancer2026-11-19

Adaptive immune microenvironment associated with prolonged disease-free interval in estrogen receptor positive breast cancer.

Wang Qichen Q, Sheahan Timothy Patrick TP, Van Alsten Sarah C SC, Cozzo Alyssa Joy AJ et al.

Adaptive immune response is associated with improved breast cancer outcomes, especially in the early interval after estrogen receptor negative (ER-) diagnoses. Long-term outcomes have seldom been evaluated. We characterized immune patterns based on predefined 48 immune genes, including adaptive and innate immune pathways, among 1899 Carolina Breast Cancer Study (CBCS) participants with long-term disease-free interval (DFI) data (with 10+ years follow-up). Latent Class Analysis, modeling both expression patterns and magnitude, identified Adaptive, Innate, and Quiet immune microenvironments. Cox proportional hazards estimated associations between immune classes and DFI in early (≤5 years) and late windows (5-10 years). Quiet immune class was significantly associated with a higher hazard of breast cancer recurrence in ER+ in both 5-year [Hazard Ratio (HR): 2.03, 95% Confidence Interval (CI): (1.16, 3.56)] and 5-to-10-year [HR: 4.93, 95% CI: (1.76, 13.77)] timeframes compared to Adaptive class. Quiet showed a similar but higher association in ER- tumors compared to Adaptive [5-year HR: 2.67 95% CI: (1.65, 4.33)]. In SCAN-B, long-term prognostic associations among ER+ breast cancers were directionally consistent with those observed in the CBCS, although effect sizes were attenuated. Classification of breast cancer microenvironments may have value for predicting long-term breast cancer prognosis.

PMID 43052316
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Nanoscale, Sub-Organellar Mapping of Lysophosphatidic Acid by Photoaffinity Labeling Reveals a Preference for ER Sheets.

Chen Po-Hsun Brian PB, Bhattacharyya Aditya A, Kong Michael M, Baskin Jeremy M JM

Lysophospholipids occupy an unusual niche in membrane biology, as they are low-abundance, nonbilayer-forming lipids that can act both as soluble extracellular agonists of G protein-coupled receptors and as transient constituents of cellular membranes. Although their roles as extracellular signaling agents are well characterized, their intracellular distributions, interactomes, and functions have remained poorly defined. Here, focusing on lysophosphatidic acid (LPA), a prototypical lysophospholipid, we have developed and applied a bifunctional LPA analog to systematically interrogate the subcellular localizations and membrane protein interactomes of LPA. By integrating chemoproteomic target identification with superresolution imaging, we uncovered a previously unappreciated suborganellar partitioning of LPA, with a preference for endoplasmic reticulum sheet domains relative to tubules. Detailed structure-function analysis of one prominent hit, CKAP4, established its single transmembrane helix as the principal determinant of LPA engagement, illustrating how this photoaffinity labeling approach can report on the nanoscale heterogeneity of the ER membrane. Collectively, this work provides a comprehensive view of the LPA interactome and suborganellar landscape, and it points to unanticipated roles for this lysolipid in cell physiology.

PMID 43053404
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多donepezil + memantine ER